Search
Nektar Therapeutics
NKTRAdd to Watchlist
70.670USD
-0.780-1.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.39BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Nektar Therapeutics is 8.80, ranking 53 out of 385 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 121.00 and a low of 98.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
153.222
Target Price
+116.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Nektar Therapeutics
NKTR
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Nektar Therapeutics's expected revenue for the next quarter?
Nektar Therapeutics's expected revenue is 10.42M.
What is Nektar Therapeutics's price target?
Analysts forecast that Nektar Therapeutics's price target is USD 105.00, with the highest forecast at USD 121.00 and the lowest forecast at USD 98.00.
How have Nektar TherapeuticsNKTR's recent earnings per share performed?
The market expectation was USD -1.82, while Nektar TherapeuticsNKTR's earnings per share (EPS) for the previous quarter was USD -1.77. EPS for the next quarter is expected at USD -1.98.
What is the analyst rating for Nektar Therapeutics?
Based on the ratings of Nektar Therapeutics's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.